Medtronic rose the most in a year after the Minneapolis-based maker of medical devices raised its earnings forecast, easing concern about slowing demand for heart devices, and said second-quarter net income jumped 59 percent to $868 million, or 78 cents a share. Revenue for defibrillators and pacemakers, mainstays of Medtronic’s core business, rose 2.9 percent to $1.28 billion. Derrick Sung, at Sanford C. Bernstein & Co., said Medtronic’s results allayed fears “that the overall cardiac market had somehow dropped off the cliff.’’ Rival Boston Scientific Inc. rose, too, by 4.8 percent.
© Copyright 2009 Globe Newspaper Company.
